Conference Coverage

Could Stem Cells Reduce Inflammatory Lesions in Patients With MS?

Neurology Reviews. 2013 July;21(7):1, 16-17

 

Suggested Reading

Auletta JJ, Bartholomew AM, Maziarz RT, et al. The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy. 2012;4(5):529-547.

Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150-156.

Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler. 2010;16(4):503-510.

Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS—progress to date. Mult Scler. 2013;19(5):515-519.

Pages

Recommended Reading

Fingolimod slows MS brain atrophy within 6 months
MDedge Neurology
Efficacy and relapse frequency affect MS drug selection
MDedge Neurology
Multiple sclerosis research in 2013: opportunities and challenges
MDedge Neurology
In MS, 44% of excess mortality is potentially preventable
MDedge Neurology
Case series finds rituximab beneficial in secondary-progressive MS
MDedge Neurology
New and Noteworthy Information—May 2013
MDedge Neurology
PEGylated Interferon Beta-1a May Reduce Annualized Relapse Rate in Patients With MS
MDedge Neurology
Peginterferon beta-1a shows promise in relapsing-remitting MS
MDedge Neurology
Acceptance of telecare for MS varied with computer experience, disease duration
MDedge Neurology
Alemtuzumab shows 'wow' factor in highly-active MS
MDedge Neurology

Related Articles